Cargando…

Elucidating the Role of Cardiac Biomarkers in COVID-19: A Narrative Evaluation with Clinical Standpoints and a Pragmatic Approach for Therapeutics

With the incidence of the unabated spreading of the COVID-19 (coronavirus disease 2019) pandemic with an increase in heart-related complications in COVID-19 patients, laboratory investigations on general health and diseases of heart have greater importance. The production of a higher level of clots...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukherjee, Sukhes, Ray, Suman Kumar, Kotnis, Ashwin, Kanwar, Jagat R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893136/
https://www.ncbi.nlm.nih.gov/pubmed/35196971
http://dx.doi.org/10.2174/1573403X18666220222144002
_version_ 1784881463311728640
author Mukherjee, Sukhes
Ray, Suman Kumar
Kotnis, Ashwin
Kanwar, Jagat R.
author_facet Mukherjee, Sukhes
Ray, Suman Kumar
Kotnis, Ashwin
Kanwar, Jagat R.
author_sort Mukherjee, Sukhes
collection PubMed
description With the incidence of the unabated spreading of the COVID-19 (coronavirus disease 2019) pandemic with an increase in heart-related complications in COVID-19 patients, laboratory investigations on general health and diseases of heart have greater importance. The production of a higher level of clots in the blood in COVID-19 individuals carries a high risk of severe lethal pneumonia, pulmonary embolism, or widespread thromboembolism. The COVID-19 pandemic has raised awareness regarding the severe consequences for the cardiac system that might cause due to severe acute respiratory distress syndrome (SARS-CoV-2). COVID-19 causes acute respiratory distress syndrome (ARDS), acute myocardial infarction, venous thromboembolism, and acute heart failure in people with preexisting cardiac illness. However, as COVID-19 is primarily a respiratory infectious disease, there is still a lot of debate on whether and how cardiac biomarkers should be used in COVID-19 patients. Considering the most practical elucidation of cardiac biomarkers in COVID-19, it is important to note that recent findings on the prognostic role of cardiac biomarkers in COVID-19 patients are similar to those found in pneumonia and ARDS studies. The use of natriuretic peptides and cardiac troponin concentrations as quantitative variables should help with COVID-19/pneumonia risk classification and ensure that these biomarkers sustain their high diagnostic precision for acute myocardial infarction and heart failure. Serial assessment of D-dimers will possibly aid clinicians in the assortment of patients for venous thromboembolism imaging in addition to the increase of anticoagulation from preventive to marginally higher or even therapeutic dosages because of the central involvement of endothelitis and thromboembolism in COVID-19. Therefore, cardiac biomarkers are produced in this phase because of some pathological processes; this review will focus on major cardiac biomarkers and their significant role in COVID-19.
format Online
Article
Text
id pubmed-9893136
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-98931362023-11-02 Elucidating the Role of Cardiac Biomarkers in COVID-19: A Narrative Evaluation with Clinical Standpoints and a Pragmatic Approach for Therapeutics Mukherjee, Sukhes Ray, Suman Kumar Kotnis, Ashwin Kanwar, Jagat R. Curr Cardiol Rev Cardiology With the incidence of the unabated spreading of the COVID-19 (coronavirus disease 2019) pandemic with an increase in heart-related complications in COVID-19 patients, laboratory investigations on general health and diseases of heart have greater importance. The production of a higher level of clots in the blood in COVID-19 individuals carries a high risk of severe lethal pneumonia, pulmonary embolism, or widespread thromboembolism. The COVID-19 pandemic has raised awareness regarding the severe consequences for the cardiac system that might cause due to severe acute respiratory distress syndrome (SARS-CoV-2). COVID-19 causes acute respiratory distress syndrome (ARDS), acute myocardial infarction, venous thromboembolism, and acute heart failure in people with preexisting cardiac illness. However, as COVID-19 is primarily a respiratory infectious disease, there is still a lot of debate on whether and how cardiac biomarkers should be used in COVID-19 patients. Considering the most practical elucidation of cardiac biomarkers in COVID-19, it is important to note that recent findings on the prognostic role of cardiac biomarkers in COVID-19 patients are similar to those found in pneumonia and ARDS studies. The use of natriuretic peptides and cardiac troponin concentrations as quantitative variables should help with COVID-19/pneumonia risk classification and ensure that these biomarkers sustain their high diagnostic precision for acute myocardial infarction and heart failure. Serial assessment of D-dimers will possibly aid clinicians in the assortment of patients for venous thromboembolism imaging in addition to the increase of anticoagulation from preventive to marginally higher or even therapeutic dosages because of the central involvement of endothelitis and thromboembolism in COVID-19. Therefore, cardiac biomarkers are produced in this phase because of some pathological processes; this review will focus on major cardiac biomarkers and their significant role in COVID-19. Bentham Science Publishers 2022-07-14 2022-07-14 /pmc/articles/PMC9893136/ /pubmed/35196971 http://dx.doi.org/10.2174/1573403X18666220222144002 Text en © 2022 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Cardiology
Mukherjee, Sukhes
Ray, Suman Kumar
Kotnis, Ashwin
Kanwar, Jagat R.
Elucidating the Role of Cardiac Biomarkers in COVID-19: A Narrative Evaluation with Clinical Standpoints and a Pragmatic Approach for Therapeutics
title Elucidating the Role of Cardiac Biomarkers in COVID-19: A Narrative Evaluation with Clinical Standpoints and a Pragmatic Approach for Therapeutics
title_full Elucidating the Role of Cardiac Biomarkers in COVID-19: A Narrative Evaluation with Clinical Standpoints and a Pragmatic Approach for Therapeutics
title_fullStr Elucidating the Role of Cardiac Biomarkers in COVID-19: A Narrative Evaluation with Clinical Standpoints and a Pragmatic Approach for Therapeutics
title_full_unstemmed Elucidating the Role of Cardiac Biomarkers in COVID-19: A Narrative Evaluation with Clinical Standpoints and a Pragmatic Approach for Therapeutics
title_short Elucidating the Role of Cardiac Biomarkers in COVID-19: A Narrative Evaluation with Clinical Standpoints and a Pragmatic Approach for Therapeutics
title_sort elucidating the role of cardiac biomarkers in covid-19: a narrative evaluation with clinical standpoints and a pragmatic approach for therapeutics
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893136/
https://www.ncbi.nlm.nih.gov/pubmed/35196971
http://dx.doi.org/10.2174/1573403X18666220222144002
work_keys_str_mv AT mukherjeesukhes elucidatingtheroleofcardiacbiomarkersincovid19anarrativeevaluationwithclinicalstandpointsandapragmaticapproachfortherapeutics
AT raysumankumar elucidatingtheroleofcardiacbiomarkersincovid19anarrativeevaluationwithclinicalstandpointsandapragmaticapproachfortherapeutics
AT kotnisashwin elucidatingtheroleofcardiacbiomarkersincovid19anarrativeevaluationwithclinicalstandpointsandapragmaticapproachfortherapeutics
AT kanwarjagatr elucidatingtheroleofcardiacbiomarkersincovid19anarrativeevaluationwithclinicalstandpointsandapragmaticapproachfortherapeutics